Literature DB >> 28283744

Serial block-face scanning electron microscopy applied to study the trafficking of 8D3-coated gold nanoparticles at the blood-brain barrier.

Itsaso Cabezón1,2,3, Elisabet Augé1,3, Manel Bosch4, Alison J Beckett5, Ian A Prior5, Carme Pelegrí1,3,6, Jordi Vilaplana7,8,9.   

Abstract

Due to the physical and physiological properties of the blood-brain barrier (BBB), the transport of neurotherapeutics from blood to brain is still a pharmaceutical challenge. We previously conducted a series of experiments to explore the potential of the anti-transferrin receptor 8D3 monoclonal antibody (mAb) to transport neurotherapeutics across the BBB. In that study, gold nanoparticles (AuNPs) were coated with the 8D3 antibody and administered intravenously to mice. Transmission electron microscopy was used and a two-dimensional (2D) image analysis was performed to detect the AuNPs in the brain capillary endothelial cells (BCECs) and brain parenchyma. In the present work, we determined that serial block-face scanning electron microscopy (SBF-SEM) is a useful tool to study the transcytosis of these AuNPs across the BBB in three dimensions and we, therefore, applied it to gain more knowledge of their transcellular trafficking. The resulting 3D reconstructions provided additional information on the endocytic vesicles containing AuNPs and the endosomal processing that occurs inside BCECs. The passage from 2D to 3D analysis reinforced the trafficking model proposed in the 2D study, and revealed that the vesicles containing AuNPs are significantly larger and more complex than described in our 2D study. We also discuss tradeoffs of using this technique for our application, and conclude that together with other volume electron microscopy imaging techniques, SBF-SEM is a powerful approach that is worth of considering for studies of drug transport across the BBB.

Entities:  

Keywords:  3D electron microscopy; Blood-brain barrier; Drug delivery; Monoclonal antibodies; Receptor-mediated transport; SBF-SEM; Transferrin receptor

Mesh:

Substances:

Year:  2017        PMID: 28283744     DOI: 10.1007/s00418-017-1553-9

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  20 in total

Review 1.  Three-dimensional volume imaging with electron microscopy toward connectome.

Authors:  Nobuhiko Ohno; Mitsuhiko Katoh; Yurika Saitoh; Sei Saitoh; Shinichi Ohno
Journal:  Microscopy (Oxf)       Date:  2014-12-30       Impact factor: 1.571

2.  Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.

Authors:  H J Lee; B Engelhardt; J Lesley; U Bickel; W M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

Review 3.  Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.

Authors:  Jason M Lajoie; Eric V Shusta
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

Review 4.  CNS drug design based on principles of blood-brain barrier transport.

Authors:  W M Pardridge
Journal:  J Neurochem       Date:  1998-05       Impact factor: 5.372

5.  In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor.

Authors:  Sarah Paris-Robidas; Vincent Emond; Cyntia Tremblay; Denis Soulet; Frédéric Calon
Journal:  Mol Pharmacol       Date:  2011-03-31       Impact factor: 4.436

6.  Study of the transcytosis of an anti-transferrin receptor antibody with a Fab' cargo across the blood-brain barrier in mice.

Authors:  Gemma Manich; Itsaso Cabezón; Jaume del Valle; Joaquim Duran-Vilaregut; Antoni Camins; Mercè Pallàs; Carme Pelegrí; Jordi Vilaplana
Journal:  Eur J Pharm Sci       Date:  2013-06-07       Impact factor: 4.384

7.  Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion.

Authors:  Wael Alata; Sarah Paris-Robidas; Vincent Emond; Fanchon Bourasset; Frédéric Calon
Journal:  Mol Pharm       Date:  2013-11-22       Impact factor: 4.939

8.  Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.

Authors:  Yun Zhang; Frederic Calon; Chunni Zhu; Ruben J Boado; William M Pardridge
Journal:  Hum Gene Ther       Date:  2003-01-01       Impact factor: 5.695

9.  Developing 3D SEM in a broad biological context.

Authors:  A Kremer; S Lippens; S Bartunkova; B Asselbergh; C Blanpain; M Fendrych; A Goossens; M Holt; S Janssens; M Krols; J-C Larsimont; C Mc Guire; M K Nowack; X Saelens; A Schertel; B Schepens; M Slezak; V Timmerman; C Theunis; R VAN Brempt; Y Visser; C J Guérin
Journal:  J Microsc       Date:  2015-01-26       Impact factor: 1.758

10.  Conductive resins improve charging and resolution of acquired images in electron microscopic volume imaging.

Authors:  Huy Bang Nguyen; Truc Quynh Thai; Sei Saitoh; Bao Wu; Yurika Saitoh; Satoshi Shimo; Hiroshi Fujitani; Hirohide Otobe; Nobuhiko Ohno
Journal:  Sci Rep       Date:  2016-03-29       Impact factor: 4.379

View more
  4 in total

1.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2017-06-06       Impact factor: 4.304

Review 2.  Cerebrovascular phenotypes in mouse models of Alzheimer's disease.

Authors:  Jenny I Szu; André Obenaus
Journal:  J Cereb Blood Flow Metab       Date:  2021-02-08       Impact factor: 6.200

3.  High-resolution Confocal Imaging of the Blood-brain Barrier: Imaging, 3D Reconstruction, and Quantification of Transcytosis.

Authors:  Roberto Villaseñor; Ludovic Collin
Journal:  J Vis Exp       Date:  2017-11-16       Impact factor: 1.355

4.  Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles.

Authors:  Kasper Bendix Johnsen; Martin Bak; Paul Joseph Kempen; Fredrik Melander; Annette Burkhart; Maj Schneider Thomsen; Morten Schallburg Nielsen; Torben Moos; Thomas Lars Andresen
Journal:  Theranostics       Date:  2018-05-24       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.